Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103798306> ?p ?o ?g. }
- W2103798306 abstract "<h3>Importance</h3> The current recommendation is for at least 12 months of dual antiplatelet therapy after implantation of a drug-eluting stent. However, the optimal duration of dual antiplatelet therapy with specific types of drug-eluting stents remains unknown. <h3>Objective</h3> To assess the clinical noninferiority of 3 months (short-term) vs 12 months (long-term) of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI) with zotarolimus-eluting stents. <h3>Design, Setting, and Patients</h3> The OPTIMIZE trial was an open-label, active-controlled, 1:1 randomized noninferiority study including 3119 patients in 33 sites in Brazil between April 2010 and March 2012. Clinical follow-up was performed at 1, 3, 6, and 12 months. Eligible patients were those with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents. <h3>Interventions</h3> After PCI with zotarolimus-eluting stents, patients were prescribed aspirin (100-200 mg daily) and clopidogrel (75 mg daily) for 3 months (n = 1563) or 12 months (n = 1556), unless contraindicated because of occurrence of an end point. <h3>Main Outcomes and Measures</h3> The primary end point was net adverse clinical and cerebral events (NACCE; a composite of all-cause death, myocardial infarction [MI], stroke, or major bleeding); the expected event rate at 1 year was 9%, with a noninferiority margin of 2.7%. Secondary end points were major adverse cardiac events (MACE; a composite of all-cause death, MI, emergent coronary artery bypass graft surgery, or target lesion revascularization) and Academic Research Consortium definite or probable stent thrombosis. <h3>Results</h3> NACCE occurred in 93 patients receiving short-term and 90 patients receiving long-term therapy (6.0% vs 5.8%, respectively; risk difference, 0.17 [95% CI, −1.52 to 1.86];<i>P</i> = .002 for noninferiority). Kaplan-Meier estimates demonstrated MACE rates at 1 year of 8.3% (128) in the short-term group and 7.4% (114) in the long-term group (HR, 1.12 [95% CI, 0.87-1.45]). Between 91 and 360 days, no statistically significant association was observed for NACCE (39 [2.6%] vs 38 [2.6%] for the short- and long-term groups, respectively; HR, 1.03 [95% CI, 0.66-1.60]), MACE (78 [5.3%] vs 64 [4.3%]; HR, 1.22 [95% CI, 0.88-1.70]), or stent thrombosis (4 [0.3%] vs 1 [0.1%]; HR, 3.97 [95% CI, 0.44-35.49]). <h3>Conclusions and Relevance</h3> In patients with stable coronary artery disease or low-risk ACS treated with zotarolimus-eluting stents, 3 months of dual antiplatelet therapy was noninferior to 12 months for NACCE, without significantly increasing the risk of stent thrombosis. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT01113372" @default.
- W2103798306 created "2016-06-24" @default.
- W2103798306 creator A5075854254 @default.
- W2103798306 date "2013-10-31" @default.
- W2103798306 modified "2023-10-17" @default.
- W2103798306 title "Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents" @default.
- W2103798306 cites W1590387607 @default.
- W2103798306 cites W17642058 @default.
- W2103798306 cites W1921048136 @default.
- W2103798306 cites W1966093874 @default.
- W2103798306 cites W1980915088 @default.
- W2103798306 cites W1982692220 @default.
- W2103798306 cites W1985483330 @default.
- W2103798306 cites W1993883684 @default.
- W2103798306 cites W1998792752 @default.
- W2103798306 cites W2001554000 @default.
- W2103798306 cites W2009589924 @default.
- W2103798306 cites W2022856209 @default.
- W2103798306 cites W2032756488 @default.
- W2103798306 cites W2033373604 @default.
- W2103798306 cites W2046209971 @default.
- W2103798306 cites W2053379248 @default.
- W2103798306 cites W2064130493 @default.
- W2103798306 cites W2072988237 @default.
- W2103798306 cites W2076602637 @default.
- W2103798306 cites W2081613030 @default.
- W2103798306 cites W2084284977 @default.
- W2103798306 cites W2087150869 @default.
- W2103798306 cites W2093397246 @default.
- W2103798306 cites W2100209149 @default.
- W2103798306 cites W2101986337 @default.
- W2103798306 cites W2103798714 @default.
- W2103798306 cites W2121908294 @default.
- W2103798306 cites W2121908836 @default.
- W2103798306 cites W2122779695 @default.
- W2103798306 cites W2127854619 @default.
- W2103798306 cites W2129118989 @default.
- W2103798306 cites W2137581001 @default.
- W2103798306 cites W2138942404 @default.
- W2103798306 cites W2144552468 @default.
- W2103798306 cites W2146743728 @default.
- W2103798306 cites W2151468302 @default.
- W2103798306 cites W2159337926 @default.
- W2103798306 cites W2162162242 @default.
- W2103798306 cites W2165349656 @default.
- W2103798306 cites W2317105686 @default.
- W2103798306 cites W2328595756 @default.
- W2103798306 cites W56850546 @default.
- W2103798306 cites W2162886638 @default.
- W2103798306 doi "https://doi.org/10.1001/jama.2013.282183" @default.
- W2103798306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24177257" @default.
- W2103798306 hasPublicationYear "2013" @default.
- W2103798306 type Work @default.
- W2103798306 sameAs 2103798306 @default.
- W2103798306 citedByCount "252" @default.
- W2103798306 countsByYear W21037983062013 @default.
- W2103798306 countsByYear W21037983062014 @default.
- W2103798306 countsByYear W21037983062015 @default.
- W2103798306 countsByYear W21037983062016 @default.
- W2103798306 countsByYear W21037983062017 @default.
- W2103798306 countsByYear W21037983062018 @default.
- W2103798306 countsByYear W21037983062019 @default.
- W2103798306 countsByYear W21037983062020 @default.
- W2103798306 countsByYear W21037983062021 @default.
- W2103798306 countsByYear W21037983062022 @default.
- W2103798306 countsByYear W21037983062023 @default.
- W2103798306 crossrefType "journal-article" @default.
- W2103798306 hasAuthorship W2103798306A5075854254 @default.
- W2103798306 hasConcept C126322002 @default.
- W2103798306 hasConcept C127413603 @default.
- W2103798306 hasConcept C141071460 @default.
- W2103798306 hasConcept C164705383 @default.
- W2103798306 hasConcept C168563851 @default.
- W2103798306 hasConcept C203092338 @default.
- W2103798306 hasConcept C2777546689 @default.
- W2103798306 hasConcept C2777628954 @default.
- W2103798306 hasConcept C2777698277 @default.
- W2103798306 hasConcept C2777849778 @default.
- W2103798306 hasConcept C2778213512 @default.
- W2103798306 hasConcept C2778583881 @default.
- W2103798306 hasConcept C2780400711 @default.
- W2103798306 hasConcept C2780645631 @default.
- W2103798306 hasConcept C2780739214 @default.
- W2103798306 hasConcept C2780797203 @default.
- W2103798306 hasConcept C45393284 @default.
- W2103798306 hasConcept C500558357 @default.
- W2103798306 hasConcept C71924100 @default.
- W2103798306 hasConcept C78519656 @default.
- W2103798306 hasConceptScore W2103798306C126322002 @default.
- W2103798306 hasConceptScore W2103798306C127413603 @default.
- W2103798306 hasConceptScore W2103798306C141071460 @default.
- W2103798306 hasConceptScore W2103798306C164705383 @default.
- W2103798306 hasConceptScore W2103798306C168563851 @default.
- W2103798306 hasConceptScore W2103798306C203092338 @default.
- W2103798306 hasConceptScore W2103798306C2777546689 @default.
- W2103798306 hasConceptScore W2103798306C2777628954 @default.
- W2103798306 hasConceptScore W2103798306C2777698277 @default.
- W2103798306 hasConceptScore W2103798306C2777849778 @default.
- W2103798306 hasConceptScore W2103798306C2778213512 @default.
- W2103798306 hasConceptScore W2103798306C2778583881 @default.